00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
01:26 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

FDA approves Acorda's Inbrija for Parkinson's

FDA approved Inbrija levodopa inhalation powder from Acorda Therapeutics Inc. (NASDAQ:ACOR) to treat "off" periods in Parkinson's disease patients receiving carbidopa/levodopa. The approval comes after multiple delays and gives Acorda a new product to bring...
00:05 , Jan 4, 2019 |  BC Innovations  |  Translation in Brief

Testing reflex vs. reality in pain

A Dana-Farber Cancer Institute team has challenged the assumptions behind standard pain models, suggesting their use contributes to poor clinical translation of pain therapies and advocating adoption of behavioral tests reflecting pain sensation instead of...
19:53 , Dec 24, 2018 |  BC Extra  |  Company News

FDA approves Acorda's Inbrija for Parkinson's

Acorda Therapeutics Inc. (NASDAQ:ACOR) said FDA approved its Inbrija levodopa inhalation powder to treat "off" periods in Parkinson's disease patients receiving carbidopa/levodopa. The approval comes after multiple delays and gives Acorda a new product to...
20:31 , Sep 14, 2018 |  BC Week In Review  |  Company News

Acorda loses Amprya appeal, reports Inbrija PDUFA delay

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $10.30 (37%) to $17.25 the week of Sept. 10 following setbacks related to multiple sclerosis drug Ampyra dalfampridine and Parkinson's disease candidate Inbrija levodopa inhalation powder (CVT-301). On Sept. 10,...
20:29 , Sep 10, 2018 |  BC Extra  |  Company News

Acorda loses appeal to shield Ampyra from generic entry

Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $6.75 (25%) to $20.80 Monday after the U.S. Court of Appeals for the Federal Circuit upheld a 2017 district court ruling that leaves multiple sclerosis drug Ampyra dalfampridine with no...
22:04 , Aug 14, 2018 |  BC Extra  |  Company News

Management tracks: Cheng departing Gilead as CMO

Gilead Sciences Inc. (NASDAQ:GILD) said CMO Andrew Cheng will leave the company, effective Sept. 7, after five months in the role to pursue another opportunity. Gilead did not say who would replace Cheng, who joined...
06:20 , Aug 10, 2018 |  BC Week In Review  |  Company News

Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under...
23:03 , Aug 6, 2018 |  BC Extra  |  Company News

Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version of multiple sclerosis drug Ampyra dalfampridine in the U.S. in 2025 or earlier under...
20:06 , Jul 27, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck At least 16 profitable biotechs and pharmas are slated to report earnings this week. (A) Fiscal 1Q; (B) Fiscal 3Q; (C) During trading hours in Europe; premarket on U.S. exchanges; (D) Six-month...